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1354Patients presenting with chest
pain and who are suspected of
having or known to have coro-
nary artery disease (CAD) require
accurate evidence of myocardial
ischemia for appropriate therapy
and improved prognosis. Both
stress echocardiography (SE) and
single-photon emission compu-
ted tomography (SPECT) are
established and widely used tech-
niques for this purpose. However,
because SPECT evaluates myo-
cardial perfusion, which becomes
abnormal earlier than wall motion
during stress, SPECT tends to be
more sensitive than SE for detec-
tion ofCAD, especially in patients
with milder CAD and single-
vessel disease (SVD) (1). Unfor-
tunately, unlike SE, SPECT
cannot be performed at thebedside, is relatively time consuming, and exposes patients to
ionizing radiation. Myocardial contrast echocardiography
(MCE) on the other hand is a rapid, radiation-free bedside
technique that provides simultaneous assessment of perfusion
and function in real time (2). MCE, which uses micro-
bubbles that mimic the rheological behavior of red blood
cells, has superior spatial and temporal resolution compared
to SPECT and is considered more sensitive for the detection
of CAD (2–4).
See page 1362
SonoVue (Bracco Imaging SpA, Milan, Italy) is a
microbubble-based ultrasonography contrast agent which
contains sulfur hexaﬂuoride gas surrounded by a lipid shell.
It is approved in Europe and elsewhere for improved
assessment of left ventricular function and structure (2).
However, large multicenter trials aimed at comparing
SonoVue-enhanced MCE and gated SPECT for CAD
detection are lacking. Thus, this large European multicenter
trial was performed in patients suspected of having ory, Royal Brompton Hospital and Northwick
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ion of Cardiology, Hospital Policlinico of Bari,known to have CAD to compare SonoVue-enhanced MCE
with gated SPECT for determination of myocardial
ischemia, using quantitative coronary angiography (CA) as
the reference standard.
Methods
Patients. Adult patients (18 years of age) suspected of
having or known to have CAD and who were referred for
testing for myocardial ischemia were assessed in a Phase III,
open-label, nonrandomized, multicenter study conducted at
34 European centers. Institutional review board and regu-
latory approval were granted, and all patients provided
written informed consent. Patients were enrolled between
May 2008 and December 2009.
Patients were ineligible if they had any clinically unstable
cardiac condition prior to SonoVue administration; if they
had any contraindications to dipyridamole or aminophylline;
any known allergy to 1 or more ingredients of SonoVue; had
previously undergone coronary artery bypass graft or any
revascularization procedure or change of clinical status that
might have warranted a change in their CAD status during
the clinical testing under evaluation; or if they ingested
methylxanthine-containing food or phosphodiesterase in-
hibitor drugs within 24 h prior to MCE or SPECT.
Patients were also excluded if the left ventricle was not
visualized at basal echocardiography or if they were pregnant
or lactating.
Image acquisition. MYOCARDIAL CONTRAST ECHOCARDIO-
GRAPHY. MCE was performed in the apical 4-, 2-, and
3-chamber views at rest and during pharmacological stress,
2 min after intravenous administration of 0.56 mg/kg
dipyridamole over 4 min. SonoVue was infused initially at
a rate of 1 ml/min using a dedicated Vueject pump (Bracco
Imaging SpA, Milan, Italy); thereafter, the rate was reduced
or increased to obtain the best possible image quality.
Images were obtained 1 min after infusion.
A ﬂash-replenishment protocol was used whereby
microbubbles were cleared from the myocardium after
achieving a steady state of infusion with a mechanical index
(MI) of 0.9. Replenishment was assessed using lower power
(MI: 0.1) imaging in real time and during end-systole-
triggered beats for 8 cardiac cycles. Images were acquired
using model IE33 equipment (Philips, Eindhoven, Best, theBari, Italy; yyyDepartment of Cardiology, Thoraxcenter, Erasmus Medical Centre,
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1355Netherlands) in 30 centers and Sequoia 512 equipment
(Siemens Medical Systems, Berlin, Germany) in 4 centers.
SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY. A
technetium (99mTc)-labeled radiopharmaceutical agent
(either 99mTc-sestamibi [Cardiolite; Lantheus Medical
Imaging; Billerica, Massachusetts] or 99mTc-tetrofosmin
[Myoview GE Healthcare; Arlington Heights, Illinois],
according to the practice of the clinical site) was adminis-
tered for the stress electrocardiography (ECG)-gated
SPECT acquisition 1 min after the end of the dipyridamole
infusion, performed either for the stress SonoVue-enhanced
MCE examination or, if this were not possible for logistical
reasons, within 24 h of the MCE examination. SPECT at
rest could be avoided if the initial stress SPECT investiga-
tion was deemed negative. If considered necessary, an
identical ECG-gated SPECT acquisition was performed at
rest within 24 h of the stress ECG-gated SPECT acquisi-
tion, following a second 99mTc-labeled radiopharmaceutical
administration. In both cases, SPECT was performed at 20
to 60 min after 99mTc-labeled radiopharmaceutical injection.
CORONARY ANGIOGRAPHY. Coronary angiography (CA) was
performed according to the standard technique in all
patients within 30 days (before or after) of the MCE
examination. In all cases, right anterior oblique and left
anterior oblique projections were acquired with both cranial
and caudal angulations to provide at least 2 orthogonal views
of each coronary artery.
Image evaluation. Images were evaluated by independent
experienced cardiologists (3 for MCE, 3 for SPECT, 1 for
CA) who were unafﬁliated with the investigational sites and
blinded to patient identity, clinical proﬁle, and to the results of
other readers and other examinations. Myocardial perfusion
by both techniques was assessed segmentally (17-segment left
ventricle [LV] model).
MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY. Qualitative
evaluation of images was performed using both real-time
and end-systole-triggered digital clips. Myocardial perfu-
sion was considered normal at rest or stress if the myocar-
dium replenished within 5 cardiac cycles at rest or within 2
cardiac cycles at stress following the ﬂash. Resting perfusion
abnormality was considered possible if there was a delay of
>5 cardiac cycles or if there was patchy or no ﬁlling at rest.
Myocardial ischemia was diagnosed if, during stress, there
was a delay of 3 cardiac cycles or if there was newly visible
patchy or subendocardial defect or absent contrast. Any
deterioration of wall motion was also considered ischemic.
SINGLE-PHOTONEMISSIONCOMPUTEDTOMOGRAPHY. SPECT
studies were reconstructed into standard views. Short-axis
slices were quantiﬁed using software for myocardial perfu-
sion (QPS) defect or contraction. The slices were displayed
in a standard format for visual and quantitative interpreta-
tion and to determine the presence and severity of
myocardial perfusion and functional defects. Segmental
tracer was assessed in rest and stress images separately, usinga semiquantitative scale in which 0 ¼ normal uptake,
1 ¼ mildly reduced uptake, 2 ¼ moderately reduced uptake,
3 ¼ severely reduced uptake, and 4 ¼ absent uptake. A
normal segment was deﬁned as a segment with score 0 or 1
at both rest and stress; myocardial ischemia was deﬁned as
a change to 2 at stress from 0/1 at rest or to 3 at stress
from 2/3 at rest. Wall motion data during gated SPECT
were also used to arrive at the diagnosis.
CORONARY ANGIOGRAPHY. A visual assessment of images
was performed to determine: 1) right coronary artery (RCA)
dominance; and 2) the presence/absence of coronary stenosis
of the LM, left anterior descending artery (LAD), left
circumﬂex artery (LCx), and RCA and their major branches
and, if present, the degree of diameter stenosis, that
is: 20%, >20% but <100%, 100% (occlusion). If stenosis
of >20% was detected in any of these vessels, quantitative
analysis was performed using dedicated QAngioXA version
7.1 software (Medical Imaging Systems).
Signiﬁcant CAD was diagnosed if a stenosis of 70% was
detected in 1 or more of these vessels. Signiﬁcant CAD was
classiﬁed as 1-, 2-, or 3-vessel disease. Patients with stenosis
of 50% were also assessed.
EFFICACY ASSESSMENTS. Segments were assigned to each of
the 3 major coronary artery territories (5). The presence of
signiﬁcant ischemia at MCE or SPECT was deﬁned when:
1) at least 2 contiguous segments; or 2) 1 segment contiguous
to at least 2 ﬁxed segments demonstrated ischemia.
SAFETY EVALUATIONS. Physical examination was performed
within 24 h prior to SonoVue administration. Monitoring
for clinical adverse events (AEs) took place from the time of
signed informed consent until 24 h after SonoVue admin-
istration. Events were classiﬁed using standard criteria. All
decisions regarding AE severity and a possible relationship
to the study agent were made by the investigator at each
center.
Measurement of vital signs (blood pressure, heart rate)
and recording of electrocardiograms (ECGs) were per-
formed within 24 h and 10 min prior to dose administration,
at the beginning and end of SonoVue infusion, at the
beginning and end of dipyridamole infusion, and at regular
time points up to 2 h after SonoVue administration.
STATISTICAL ANALYSIS. The primary aim was to demonstrate
noninferiority (5% of difference) for MCE relative to
SPECT in terms of sensitivity and speciﬁcity for the detec-
tion of 70% coronary artery stenosis. Assuming a power of
80%, a 1-sided signiﬁcance level (alpha) of 2.5%, expected
sensitivity and speciﬁcity values for SPECT of 71%, an ex-
pected maximum proportion of discordant pairs of 20%, and
an expected prevalence of positive and negative patients of 70%
(patients with at least 1 stenosis of 70%) and 30%, respec-
tively, sample sizes of 230 for sensitivity and 537 for speciﬁcity
were calculated. Taking the higher number and assuming
a maximum patient dropout rate of 10%, a mini-
mum enrollment of 597 patients was considered necessary. As
Table 1 Patient Characteristics of the Study Population
Age (yrs) 63  10
Men 381 (74)
Chest pain 343 (67)
Chest pain on exertion 265 (51)
Hypertension 388 (75)
Diabetes mellitus 149 (29)
Hyperlipidemia 372 (72)
Smoking history 294 (57)
Previous AMI 136 (26)
Previous PCI 198 (38)
BMI (kg/m2) 27  4
No. of patients with 1 CV risk factor 511 (99)
Prevalence of 70% CAD 161 (31)
Single-vessel disease 131 (81)
Multivessel disease 30 (19)
Proximal disease 50 (31)
Location of 70% CAD
LAD 54 (34)
LCx 61 (38)
RCA 80 (50)
Prevalence of 50% CAD 310 (60)
Prevalence of 20% CAD 385 (75)
Values are mean  SD or n (%).
AMI ¼ acute myocardial Infarction; CAD ¼ coronary artery disease; CV ¼ cadiovascular; LAD ¼
left anterior descending artery; LCx ¼ left circumﬂex artery; PCI ¼ percutaneous coronary inter-
vention; RCA ¼ right coronary artery.
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determinations for this cutoff were also performed.
The ﬁndings from the 3 independent readers were
collapsed into 1 record per patient for both MCE and
SPECT, using a majority rule, that is, the result was positive
or negative if the diagnosis was positive or negative for at
least 2 readers, respectively. Technically inadequate or
nonevaluable coronary artery territories were considered false
negative if a stenosis of 70% was detected at CA or as false
positive if no stenosis or a stenosis of <70% was detected at
CA. The test of noninferiority (5% of difference) for
MCE relative to SPECT was performed by using the score
method proposed by Nam (6) for noninferiority testing
based on the difference of paired proportions. The McNe-
mar test was used to assess the signiﬁcance of differences
between MCE and SPECT in terms of sensitivity, speci-
ﬁcity, and accuracy for detection of CAD. Inter-reader
agreement was determined using generalized weighted
kappa (k) statistics.
All statistical analyses and data processing were performed
using SAS software (release 9.2, library V9, SAS Institute,
Cary, North Carolina) on a Windows XP (Microsoft Corp.,
Redmond, Washington) service pack 3 Pro operating system
(Microsoft Inc., Seattle, Washington). A p value of <0.05
was considered signiﬁcant.
Results
A total of 628 of 630 enrolled patients received SonoVue
and comprised the safety population. Of these 628 patients,
80 did not undergo CA. Another 6 patients had inadequate
CA images. Of the 542 patients with adequate CA, 22 and
4 patients did not undergo SPECT and stress MCE,
respectively. Thus, a total of 516 patients underwent all 3
procedures and fulﬁlled the prospectively deﬁned efﬁcacy
population (Table 1). Of these 516 patients, 422 (81.7%)
underwent MCE using the Philips system and 94 (18.2%)
using the Siemens system.
Coronary angiography. At CA, 161 (31.2%) patients
had 70% stenosis. These 161 patients included 131 (81%)
with SVD and 30 (19%) with multivessel disease (MVD)
(26 with 2-vessel; 4 with 3-vessel disease). CAD with 50%
stenosis was present in 310 (60.1%) patients.
Diagnostic performance of MCE and SPECT. Sensi-
tivity for the detection of 70% stenosis across 3 blinded
readers ranged from 67.1% to 75.2% for MCE and from
31.1% to 70.8% for SPECT. Conversely, the speciﬁcity of
MCE was lower than that of SPECT with values across 3
blinded readers ranging from 47.6% to 53.5% for MCE and
from 59.2% to 85.4% for SPECT. Based on the 3 readers’
collapsed data (Fig. 1) the sensitivity for CAD detection was
signiﬁcantly higher for MCE than for SPECT (75.2% [95%
conﬁdence interval {CI}: 68.5 to 81.8%] vs. 49.1% [95%
CI: 41.3 to 56.8%]; p< 0.0001) with no differences between
vendors (76%, Philips vs. 74%, Siemens). Conversely, the
speciﬁcity of MCE was lower than that of SPECT (52.4%[95% CI: 46.2 to 58.6%] vs. 80.6% [95% CI: 77.4 to 83%];
p< 0.0001) again with no differences between vendors (53%
vs. 50%; Philips vs. Siemens, respectively). The data sup-
ported the noninferiority of MCE to SPECT in terms of
sensitivity (p< 0.0001) but did not support the noninferiority
of MCE for speciﬁcity (p ¼ 1.000). Similar results were ob-
tained in patients with50% CAD (Fig. 2); the sensitivity of
MCE was again signiﬁcantly (p< 0.0001) superior to that of
SPECT, while speciﬁcity was inferior. Notably, both MCE
and SPECT showed improved sensitivity with increasing
grades of stenosis (Fig. 2A), while speciﬁcity decreased with
increasing grades of stenosis (Fig. 2B).
In terms of accuracy, MCE was less accurate than
SPECT for the detection of 70% stenosis (59.5% vs.
70.7%, p < 0.0001) but was signiﬁcantly more accurate
for the detection of 50% stenosis (62.8% vs. 52.9%,
p < 0.0001). Given that the prevalence of disease was 60%
in the population with 50% stenosis compared with only
30% in the population with 70% stenosis, the accuracy
measurements should be considered more relevant for the
former group.
Among 380 patients with no history of acute myocardial
infarction (AMI), the sensitivity of MCE compared with
SPECT for the detection of 70% stenosis was 66.0%
versus 44.3%, respectively
(p < 0.0001), while the speciﬁcity was 57.3% versus 83.2%,
respectively (p < 0.0001).
The sensitivity of MCE was superior to that of SPECT,
independently of the extent of disease (Fig. 3). However,
MCE superiority was most marked among the 131 patients
Figure 3
Sensitivity for CAD (70% Stenosis) Detection by
Disease Extent
MCE was signiﬁcantly superior to SPECT in patients with single-vessel and prox-
imal disease. Superiority in patients with multivessel disease was not signiﬁcant
because of low patient numbers. Abbreviations as in Figure 1.
Figure 1
MCE Versus SPECT for Detection of
Signiﬁcant (70% Stenosis) CAD
The sensitivity of myocardial contrast echocardiography (MCE) was signiﬁcantly
superior to that of single-photon emission computed tomography (SPECT) for
coronary artery disease (CAD) detection, although speciﬁcity was lower.
JACC Vol. 62, No. 15, 2013 Senior et al.
October 8, 2013:1353–61 CAD Detection by Myocardial Contrast Echo vs. SPECT
1357with SVD (72.5% vs. 42.7%, respectively; p < 0.0001).
Although MCE also was superior to SPECT among the 30
patients with MVD (86.7% vs. 76.7%, respectively),
signiﬁcance was not demonstrated because of the small
number of patients with MVD. Signiﬁcantly superior
sensitivity of MCE compared to SPECT was also demon-
strated in patients with proximal CAD (80% vs. 58%,
respectively; p ¼ 0.005) (Fig. 3).Figure 2
MCE Versus SPECT for Detection of
50%, 70%, and 90% Stenoses
The sensitivity (A) of MCE for CAD detection was signiﬁcantly superior to that of
SPECT for all grades of stenosis, although speciﬁcity (B) was lower. Note that the
sensitivity of both techniques increased with increasing grade of stenosis, while
the speciﬁcity of both techniques decreased. Abbreviations as in Figure 1.The sensitivity of MCE was likewise signiﬁcantly superior
to that of SPECT, independently of the location of disease
(in 45 of 54 patients [83.3%] vs. 28 of 54 patients [51.9%]
patients, respectively, with LAD disease [p ¼ 0.0007]; in 48
of 61 [78.7%] vs. 36 of 61 patients [59%], respectively, with
LCx disease [p ¼ 0.0027]; and in 58 of 80 patients (72.5%)
vs. 42 of 80 patients [52.5%], respectively, with RCA disease
[p ¼ 0.0011]) (Fig. 4).
Concerning CAD localization at the patient level, the
sensitivity of MCE versus that of SPECT was 65% versus
41% (p ¼ 0.005), respectively, in the LAD territory and 53%
versus 43% (p ¼ 0.0641), respectively, in the RCA/LCx
territory. Corresponding speciﬁcities were 71% versus 91%
(p< 0.0001) and 67% versus 88% (p< 0.0001), respectively.
An example of a patient with signiﬁcant reversible defect
of the inferior wall on MCE corresponding to an 80%
stenosis of the RCA on quantitative CA and in which
SPECT revealed no abnormalities is shown in Figure 5.
Interobserver agreement (k value) for the detection of
70% CAD at the patient level was k ¼ 0.37 for the 3
MCE readers and k ¼ 0.34 for the 3 SPECT readers. The
percentage agreement for any 2 readers ranged from 60% to
84% for MCE and from 65% to 87% for SPECT.Figure 4
Sensitivity for CAD (70% Stenosis) Detection
by Vascular Territory
MCE was signiﬁcantly superior to SPECT for detection of signiﬁcant CAD regard-
less of disease location. Abbreviations as in Figure 1.
Figure 5 MCE Versus SPECT for Detection of Signiﬁcant CAD
A 52-year-old man with signiﬁcant reversible defect of the inferior wall shown by MCE at rest (A) and under stress (B), corresponding to an 80% stenosis of the right coronary
artery (RCA) on quantitative coronary angiography (CA) (C). SPECT (D) revealed no abnormalities. Abbreviations as in Figure 1.
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1358Safety. Nonserious AEs considered related to SonoVue
administration were noted in 16 (2.5%) patients. AEs were
considered mild in 11 (1.8%) patients. The most frequent
nonserious AEs were nausea and headache, which were
reported by 4 (0.6%) and 3 (0.5%) patients, respectively. A
solitary serious event considered possibly related to SonoVue
administration was reported in a 69-year-old female patient
with systolic hypertension and suspected myocarditis. After
successfully undergoing rest and stress echocardiography, the
patient developed hypersensitivity-like symptoms and asys-
tole for 30 s. All symptoms were successfully treated. The
duration of the event from the ﬁrst symptom (pale, sweating)
to complete, symptom-free recovery was 57 min. Changes in
vital sign and ECG parameters were infrequent and small.
Discussion
This large multicenter prospective trial revealed superior
sensitivity but lower speciﬁcity for SonoVue-enhanced
MCE compared to gated SPECT for the detection of
CAD in a population with predominant symptoms of
chest pain, a high incidence of CV risk factors, and an
intermediate-high prevalence of CAD. The greater sensi-
tivity of MCE compared to that of SPECT was indepen-
dent of the severity of CAD and increased signiﬁcantlywith higher grades of stenosis. Notably, the superior sensi-
tivity of MCE over SPECT was particularly marked in
patients with SVD, which was highly prevalent in our
population with CAD. The superior sensitivity of MCE was
also notable in patients with proximal disease and was
independent of arterial location; signiﬁcantly greater sensi-
tivity was apparent not only in patients with disease of the
LAD but also in patients with disease of the inferoposterior
circulation.
Conversely, the speciﬁcity of MCE was lower than that of
SPECT. In part this may be due to the sensitivity of MCE,
which was higher than that of SPECT, for the detection of
microvascular abnormalities. Notably, 51% of patients in our
population complained of chest pain on exertion, and almost
all had at least one cardiovascular risk factor. Given that
approximately 75% of our population demonstrated some
degree of CAD (20% diameter stenosis in a major vessel),
underlying microvascular disease in most patients should be
considered highly likely (7).
Comparative mechanism of MCE versus SPECT for
detection of CAD. MCE utilizes microbubbles which
rheologically mimic red blood cells and remain entirely
intravascular. During steady state when contrast agent is
infused continuously, the signal intensity from the myocar-
dium depicts capillary blood volume (8). Flash imaging,
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1359which results in a transient increase in acoustic power, clears
the microbubbles from the myocardium. When this is fol-
lowed by low power imaging, microbubbles can be seen
replenishing the myocardium with minimal destruction.
Capillary blood velocity at rest is 1 mm/s (9). Because the
imaging sector produced by the echocardiographic trans-
ducer has an elevation of 5 mm, a capillary length of 5 mm is
imaged. Thus, at rest, it requires 5 s for the capillaries to
replenish after clearance during transient high-power
imaging. During hyperemia (during dipyridamole infu-
sion), capillary blood velocity increases by 4 to 5 times
compared to that at rest in the absence of a ﬂow-limiting
stenosis. Thus, myocardium in the absence of ﬂow limita-
tion replenishes in 1 s. In myocardium subtended by ﬂow-
limiting stenosis, this process takes >1 s (9). Furthermore,
in myocardium subtended by ﬂow-limiting stenosis, de-
recruitment of capillaries occurs and is depicted by reduced
signal intensity on MCE (10). Thus, the hallmark of ﬂow-
limiting CAD during MCE is a reduction of signal inten-
sity with slow replenishment. The reduction in signal
intensity is very marked in the subendocardium with slow
ﬁlling progressing from epicardium to endocardium (11).
Because MCE has excellent spatial and temporal resolution,
this phenomenon can be detected easily.
On the other hand, SPECT detects ischemia based on
differential tracer uptake compared with regions of normal
uptake. Because of attenuation and Compton scatter, error
in the measurement of counts in closed chest patients is
approximately 30%. Therefore, a perfusion defect must be of
at least this magnitude to be detected by SPECT. Thus, in
patients with mild stenosis, differential tracer uptake may
not be discernible. Furthermore, uptake of the 99mTc agents
MIBI and tetrofosmin reach plateaus, even if the myocardial
blood ﬂow increases several times over that of rest ﬂow
(12,13). Hence, if stenosis is mild, the plateau effect of tracer
uptake will not produce detectable differences in tracer
uptake. Finally, the signiﬁcantly lower spatial resolution of
SPECT precludes adequate appreciation of subendocardial
defects which are more common in patients with mild
stenosis. Unlike MCE, SPECT has no temporal resolution.
Therefore, it is not possible to detect phenomena dependent
on myocardial blood velocity. In patients with mild-to-
moderate stenosis, the capillary blood volume changes are
relatively small compared to changes in myocardial blood
velocity (9). This is true also in patients with microvascular
disease (14). These drawbacks of SPECT are likely reasons
for the lower sensitivity of this technique compared with
MCE, particularly in a CAD population with a high prev-
alence of SVD and likely high prevalence of microvascular
disease. Our ﬁndings conﬁrm ﬁndings of recent single and
multicenter studies that have also demonstrated superior
sensitivity of MCE for the detection of CAD (2–4).
The sensitivity of SPECT in this study was comparable to
values obtained in similarly conducted large multicenter
studies (4,15). In a recent multicenter study that compared
cardiac magnetic resonance (CMR) imaging with SPECT,the sensitivity of SPECT was 59% (15). In another multi-
center trial, the sensitivity of SPECT was 61% (4). In both
of those studies, the prevalence of MVD (40%) was roughly
twice that in our study. This partly explains the slightly
lower sensitivity of SPECT (49%) in our study. Further-
more, in our study, only reversible defects were considered
for the diagnosis of signiﬁcant CAD; in the aforementioned
trials, both rest and reversible defects formed the basis of an
abnormal SPECT scan. This may also explain the slightly
better sensitivity of SPECT in those previous trials. On the
other hand, another large single-center study that compared
CMR and SPECT for the detection of signiﬁcant CAD
(>70% diameter stenosis) determined a sensitivity of 50%
and a speciﬁcity of 80% for SPECT on the ROC curve
which is similar to the values obtained in our study in
a similar patient cohort (16). In all these studies low sensi-
tivity of SPECT can also be attributed to the use of vaso-
dilator only rather than the more widely clinically used
combination of vasodilator and low-level exercise.
Better sensitivity and speciﬁcity values for both MCE and
SPECT have been obtained in single-center studies than in
this and other multicenter studies. This can be attributed to
the fact that images in large multicenter studies are analyzed
in blinded fashion, with readers completely unaware of
patient characteristics. This is in contrast to the routine
situation in a clinical environment in which patient data and
the results of other imaging studies are readily available
resulting in better performance for both techniques.
Safety of SonoVue. The safety proﬁle of SonoVue in this
study was excellent. Adverse events considered possibly
related to SonoVue occurred in just 2.5% of patients. Most
events were minor with the most frequent being nausea and
headache. This safety proﬁle should be considered excellent
for an ultrasound contrast agent that is widely used clinically
to improve assessment of cardiac structure and function,
particularly in conjunction with stress echocardiography.
Study strengths and limitations. The strengths of our
study were its large patient cohort (largest MCE study to
date), multicenter design, and use of echocardiographs from 2
vendors (no differences were apparent in terms of MCE
diagnostic performance). Furthermore, the protocol used for
MCE image acquisition and analysis was that recommended
for clinical use by the European Association of Echocardi-
ography (2). Reproducibility among the MCE readers was
similar to that among the readers for SPECT, a technique
which is already verymature andwidely used. These results are
similar to those obtained in a previous multicenter trial (4).
There are a few limitations. The standard of reference for
this study was quantitative CA. Although measurement of
the fractional ﬂow reserve (FFR) is considered superior to
lumen measurement for determination of coronary stenoses
(17), FFR was not yet in routine use when this study began.
On the other hand, dissociation between FFR and
myocardial ischemia assessed by SE or nuclear imaging has
also been noted (18). Another limitation of our study is that
MCE evaluation did not differentiate between perfusion and
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1360wall motion assessment. Thus, the inﬂuence of wall motion
alone on the diagnostic accuracy of MCE was not deter-
mined. A reversible abnormality was the criterion for de-
tection of CAD. It is very unlikely that a reversible wall
motion abnormality could have inﬂuenced the result because
the low dose of dipyridamole used in this trial, which is
optimal for vasodilatory response and hence for perfusion
assessment, induces only infrequent wall motion abnormal-
ities, particularly in patients with mild disease which was the
dominant disease condition in the study (19–21). While
baseline wall motion abnormality could have inﬂuenced the
readers to err on the side of abnormality, excluding patients
with previous AMI did not signiﬁcantly alter the overall
result. Despite a much lower prevalence of signiﬁcant CAD
than expected, differences in sensitivity and speciﬁcity
between MCE and SPECT were relatively large. Notably,
although similar ﬁndings for sensitivity and speciﬁcity to
those obtained in patients with 70% stenosis were ob-
tained in patients with 50% stenosis, the overall accuracy
was signiﬁcantly superior for MCE compared to SPECT.
This can be considered a reﬂection of the greater prevalence
of disease (60%) among patients with 50% stenosis.
Finally, only 3% of SPECT studies were considered non-
evaluable compared with 0% of MCE studies. Excluding
nonevaluable patients would therefore have little impact on
the overall ﬁndings of the study.
Clinical implications. SPECT and SE are widely used for
the assessment of myocardial ischemia. However, SPECT,
unlike SE, requires ionizing radiation, is not a bedside
procedure, and is relatively more costly and time consuming.
On the other hand, SE has lower sensitivity than SPECT,
particularly in patients with SVD (1). This study showed that
perfusion assessed by MCE had a superior sensitivity
compared to SPECT for the detection of CAD. Thus, MCE
is likely to enhance sensitivity when used in conjunction with
SE. The speciﬁcity of MCE may also improve particularly if
used during dobutamine SE as mildly abnormal perfusion in
the presence of normal wall motion may not be indicative of
signiﬁcant CAD. Furthermore, prognosis is better in such
patients than in patients with additional wall motion abnor-
mality, as this combination reﬂects signiﬁcant CAD (22).
Nevertheless, it has been shown that patients with a reversible
perfusion defect alone have a worse outcome than patients
with normal wall motion and perfusion (21). This is possibly
because such patients may not have ﬂow-limiting CAD but
rather a microcirculation abnormality as the cause of chest
pain. Such patients have been shown to have a worse outcome
than those with no evidence of ischemia (23). Antianginal
therapy may be appropriately instituted in such patients with
chest pain and ischemia but non-ﬂow-limiting CAD.
Conclusions
In this multicenter study in a broad, unselected population
of patients with predominant symptoms of chest pain, a high
incidence of CV risk factors and an intermediate-highprevalence of CAD, SonoVue-enhanced MCE was safe and
signiﬁcantly more sensitive than gated SPECT for the
detection of CAD.
Reprint requests and correspondence: Prof. Roxy Senior,
Department of Cardiology, Royal Brompton Hospital, London,
Cardiovascular Biomedical Research Unit, NHLI, Imperial
College, Sydney Street, London SW36NP, United Kingdom.
E-mail: roxysenior@cardiac-research.org.REFERENCES
1. Marwick TH. Stress echocardiography. Heart 2003;89:113–8.
2. Senior R, Becher H, Monaghan M, et al. Contrast echocardiography:
evidence-based recommendations by European Association of Echo-
cardiography. Eur J Echocardiogr 2009;10:194–212.
3. Peltier M, Vancraeynest D, Pasquet A, et al. Assessment of the
physiologic signiﬁcance of coronary disease with dipyridamole real-
time myocardial contrast echocardiography. Comparison with
technetium-99m sestamibi single-photon emission computed tomog-
raphy and quantitative coronary angiography. J Am Coll Cardiol 2004;
43:257–64.
4. Senior R, Monaghan M, Main ML, et al. Detection of coronary
artery disease with perfusion stress echocardiography using a novel
ultrasound imaging agent: two phase 3 international trials in
comparison with radionuclide perfusion imaging. Eur J Echocardiogr
2009;10:26–35.
5. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized
myocardial segmentation and nomenclature for tomographic imaging
of the heart: a statement for healthcare professionals from the Cardiac
Imaging Committee of the Council on Clinical Cardiology of the
American Heart Association. Circulation 2002;105:539–42.
6. Nam J. Establishing equivalence of two treatments and sample size
requirements in matched-pairs design. Biometrics 1997;53:1422–30.
7. Pepine CJ, Douglas PS. Rethinking stable ischemic heart disease: is
this the beginning of a new era? J Am Coll Cardiol 2012;60:957–9.
8. Wei K, Jayeweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Basis
for detection of stenosis using venous administration of microbubbles
during myocardial contrast echocardiography: bolus of continuous
infusion? J Am Coll Cardiol 1998;32:252–60.
9. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S.
Quantiﬁcation of myocardial blood ﬂow with ultrasound-induced
destruction of microbubbles administered as a constant venous infu-
sion. Circulation 1998;97:473–83.
10. Jayaweera AR,Wei K, CogginsM, Bin JP, GoodmanC, Kaul S. Role of
capillaries in determining CBF reserve: new insights using myocardial
contrast echocardiograpny. Am J Physiol 1999;277:H2363–72.
11. Linka AZ, Sklenar J, Wei K, Jayaweera AR, Skyba DM, Kaul S.
Assessment of transmural distribution of myocardial perfusion with
contrast echocardiography. Circulation 1998;98:1912–20.
12. Glover DK, Beller GA, Cunningham M, et al. Comparison between
201 TI and 99m Tc sesamibi uptake during adenosine induced vaso-
dilation as a function of coronary stenosis severity. Circulation 1995;91:
813–20.
13. Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced
detection of reversible perfusion defects byTc-99m sestamibi compared to
Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-
to-moderate coronary artery disease. J AmColl Cardiol 2001;37:458–62.
14. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S.
Decrease in coronary blood ﬂow reserve during hyperlipidemia is
secondary to an increase in blood viscosity. Circulation 2001;104:
2704–9.
15. Schwitter J, Wacker CM, Wilke N, et al. MR-IMPACT II: magnetic
resonance imaging for myocardial perfusion assessment in coronary
artery disease trial: perfusion-cardiac magnetic resonance vs. single-
photon emission computed tomography for the detection of coronary
artery disease: a comparative multicenter multivendor trial. Eur Heart J
2013;34:775–81.
16. Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic
resonance and single-photon emission computed tomography for
JACC Vol. 62, No. 15, 2013 Senior et al.
October 8, 2013:1353–61 CAD Detection by Myocardial Contrast Echo vs. SPECT
1361diagnosis of coronary heart disease (CE-MARC): a prospective trial.
Lancet 2012;379:453–60.
17. Pijls NH, Fearon WF, Tonino PA, et al. Fractional ﬂow reserve versus
angiography for guiding percutaneous coronary intervention in patients
with multivessel coronary artery disease: 2-year follow-up of the FAME
(Fractional Flow Reserve Versus Angiography for Multivessel Evalu-
ation) study. J Am Coll Cardiol 2010;56:177–84.
18. Johnson NP, Kirkeeide RL, Gould KL. Is discordance of coronary ﬂow
reserve and fractionalﬂow reserve due tomethodology or clinically relevant
coronary pathophysiology? J Am Coll Cardiol Img 2012;5:193–202.
19. Bin JP, Le E, Pelberg RA, Coggins MP, Wei K, Kaul S. Mechanism
of inducible regional dysfunction during dipyridamole stress. Circula-
tion 2002;106:112–7.
20. Fung AV, Gallagher KP, Buda AJ. The physiologic basis of dobut-
amine compared with dipyridamole stress interventions in the assess-
ment of critical coronary stenosis. Circulation 1987;76:943–51.
21. Soman P, Lahiri A, Senior R. Vasodilator stress induces infrequent
wall thickening abnormalities compared to perfusion defects inmild-to-moderate coronary artery disease: implications for the choice of
imaging modality with vasodilator stress. Echocardiography 2004;21:
207–12.
22. Tsutsui JM, Elhendy A, Anderson JR, Xie F, McGrain AC,
Porter TR. Prognostic value of dobutamine stress myocardial contrast
perfusion echocardiography. Circulation 2005;112:1444–50.
23. Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Stable angina pectoris
with no obstructive coronary artery disease is associated with increased
risks of major adverse cardiovascular events. Eur Heart J 2012;33. 734–4.Key Words: contrast echocardiography - ischemia - SonoVue.
APPENDIX
For a list of investigators enrolling patients in the study, please see the
online version of this article.
